NASDAQ, MYGN - Myriad Genetics Inc
We are a leading healthcare company focused on the development and marketing of
novel molecular diagnostic and therapeutic products. We employ a number of
proprietary technologies that permit us to understand the genetic basis of human
disease and the role that genes and their related proteins play in the onset,
progression and treatment of disease. We use this information to guide the
development of new healthcare products that are designed to treat disease and
assess a person?s risk of disease later in life.
Our molecular diagnostic business focuses on the analysis of genes and their
alterations to assess an individual?s risk for developing disease later in life
(predictive medicine) and to assess a patient?s risk of disease progression,
disease recurrence, drug toxicity, and drug response (personalized medicine). To
date we have launched five commercial molecular diagnostic products, including
both predictive medicine and personalized medicine products. ...
Read SEC Filing on NASDAQ.com »